049180 — Cellumed Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Cellumed Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	99,918	122,085	95,553	129,140	140,194
Cost of Revenue
Gross Profit	14,362	13,631	5,632	9,489	6,553
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	91,778	123,436	121,124	157,877	138,831
Operating Profit	8,140	-1,351	-25,571	-28,737	1,363
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,076	-4,800	-38,581	-32,085	-2,224
Provision for Income Taxes
Net Income After Taxes	8,259	-5,184	-37,927	-31,817	-2,184
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	8,181	-5,571	-37,298	-31,545	-2,236
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,181	-5,571	-37,298	-31,545	-2,236
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	127	-157	-645	-355	-119
Dividends per Share